ABT vs ADP Stock Comparison

Scores Breakdown

Metric	ABT	ADP
📈 Growth	22/30	22/30
💰 Profitability	17/20	18/20
🏦 Financial Health	15/20	9/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	4/10	6/10
Overall Score	72/100	67/100

Side-by-Side Summaries

ABT Analysis	ADP Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Across eight quarters, ADP's revenue hovered around $5.25B–$5.56B, finishing at about $5.359B in the latest quarter, a modest gain from the start. Net income rose from roughly $956.3M to $1.062B, an ~11% increase. There was a mid-period dip in 2025 Q4, but the longer trajectory remains stable-to-up with solid profitability. 💰 Margins & Cash Flow Gross Margin fluctuated roughly 45%–52%, averaging around the mid-40s to high-40s. Operating Margin consistently around 23% in recent quarters. Net Margin near 19–20%. Operating cash flow remains solid around $1.0–$1.4B per quarter; net cash flow is affected by financing activity in some periods, with a large financing inflow in the latest quarter. 🛡️ Balance Sheet & Liquidity Total assets generally in the mid-to-high $50B range; liabilities near $50–$60B and equity around $4–$6B, yielding a modest liquidity buffer as current assets roughly equal current liabilities. Leverage is elevated but cash generation is steady. ⚠️ Key Drivers & Risks Drivers: Recurring payroll/data processing services; broad client base and scale advantages. Risks: Regulatory/macro shifts and reliance on financing activity in some periods, creating sensitivity to funding costs and leverage.

ABT Analysis

ADP Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Across eight quarters, ADP's revenue hovered around $5.25B–$5.56B, finishing at about $5.359B in the latest quarter, a modest gain from the start. Net income rose from roughly $956.3M to $1.062B, an ~11% increase. There was a mid-period dip in 2025 Q4, but the longer trajectory remains stable-to-up with solid profitability.

💰 Margins & Cash Flow

Gross Margin fluctuated roughly 45%–52%, averaging around the mid-40s to high-40s.
Operating Margin consistently around 23% in recent quarters.
Net Margin near 19–20%.
Operating cash flow remains solid around $1.0–$1.4B per quarter; net cash flow is affected by financing activity in some periods, with a large financing inflow in the latest quarter.

🛡️ Balance Sheet & Liquidity

Total assets generally in the mid-to-high $50B range; liabilities near $50–$60B and equity around $4–$6B, yielding a modest liquidity buffer as current assets roughly equal current liabilities. Leverage is elevated but cash generation is steady.

⚠️ Key Drivers & Risks

Drivers: Recurring payroll/data processing services; broad client base and scale advantages.
Risks: Regulatory/macro shifts and reliance on financing activity in some periods, creating sensitivity to funding costs and leverage.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"